CELEX: 62016TA0044
Language: en
Date: 2018-01-31 00:00:00
Title: Case T-44/16: Judgment of the General Court of 31 January 2018 — Novartis AG v EUIPO — SK Chemicals (Figurative EU trade mark representing a transdermal patch) (EU trade mark — Invalidity proceedings — Figurative EU trade mark representing a transdermal patch — Absolute ground for refusal — Sign consisting exclusively of the shape of the product necessary to obtain a technical result — Article 7(1)(e)(ii) of Regulation (EC) No 207/2009 (now Article 7(1)(e)(ii) of Regulation (EU) 2017/1001))

12.3.2018   
            
            
               EN
            
            
               Official Journal of the European Union
            
            
               C 94/17
            
         Judgment of the General Court of 31 January 2018 — Novartis AG v EUIPO — SK Chemicals (Figurative EU trade mark representing a transdermal patch)
   
   (Case T-44/16) (1)
   
   ((EU trade mark - Invalidity proceedings - Figurative EU trade mark representing a transdermal patch - Absolute ground for refusal - Sign consisting exclusively of the shape of the product necessary to obtain a technical result - Article 7(1)(e)(ii) of Regulation (EC) No 207/2009 (now Article 7(1)(e)(ii) of Regulation (EU) 2017/1001)))
   (2018/C 094/21)
   Language of the case: English
   
      Parties
   
   
      Applicant: Novartis AG (Basle, Switzerland) (represented: initially by M.R. Douglas, and subsequently by A. Nordemann-Schiffel, lawyers)
   
      Defendant: European Union Intellectual Property Office (represented by: H. Kunz, acting as Agent)
   
      Other party to the proceedings before the Board of Appeal of EUIPO intervening before the General Court: SK Chemicals GmbH (Eschborn, Germany) (represented by: R. Dissmann, J. Bogatz, and C. Lindenthal, lawyers)
   
      Re:
   
   Action brought against the decision of the Fifth Board of Appeal of EUIPO of 27 November 2015 (Case R 2342/2014-5), relating to invalidity proceedings between SK Chemicals and Novartis.
   
      Operative part of the order
   
   
               1.
            
            
               Dismisses the action;
            
         
               2.
            
            
               Orders Novartis AG to pay the costs.
            
         
      (1)  OJ C 111, 29.3.2016.